12:00 AM
 | 
Apr 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ixmyelocel-T: Completed Phase IIb enrollment

Aastrom completed enrollment of 86 patients in the double-blind, placebo-controlled, U.S. Phase IIb RESTORE-CLI trial evaluating intramuscular injections of VRCs. In February, the company reported interim data from 46 evaluable patients showing that VRCs met the composite secondary efficacy...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >